Skip to main content
SpringerLink
Log in

Viral Infection

  • Chapter
  • First Online:
The Infectious Diseases Consult Handbook

  • 290 Accesses

Abstract

Viruses are agents that contain machinery allowing them to replicate within host cells, often to the detriment of those infected. The impact of viral infections can range from relatively benign, such as the common cold, to devastating and lethal, such as hantavirus. Unlike bacterial and fungal microorganisms, there are less available therapeutics for viral infection. Diagnostics continue to improve although are often based on nucleic acid testing so may not be agnostic if infection is caused by a virus for which common assays do not contain primers.

In this century, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease it causes, coronavirus disease 2019 (COVID-19), have caused a massive pandemic with high rates of global morbidity and mortality. During my time in fellowship, writing my notes about diagnostics and treatments for SARS-CoV-2 felt like describing shipbuilding while aboard the Titanic. As a field, clinical virology has made large strides in response to the pandemic, although there is still much work to be done. In this chapter, we will discuss common hepatitis viruses; examine some concepts involving herpesviruses, cytomegalovirus, and adenovirus; and review the management of COVID-19.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Conners EE, Panagiotakopoulos L, Hofmeister MG, Spradling PR, Hagan LM, Harris AM, Rogers-Brown JS, Wester C, Nelson NP, Rapposelli K, Sandul AL, Choi E, Coffin C, Marks K, Thomas DL, Wang SH. Screening and testing for hepatitis B virus infection: CDC recommendations—United States, 2023. MMWR Recomm Rep. 2023;72:1–25. https://doi.org/10.15585/mmwr.rr7201a1.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Davison SA, Strasser SI. Ordering and interpreting hepatitis B serology. BMJ. 2014;348:g2522. https://doi.org/10.1136/bmj.g2522.

    Article  CAS  PubMed  Google Scholar 

  3. Pattyn J, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccines. J Infect Dis. 2021;224:S343–51. https://doi.org/10.1093/infdis/jiaa668.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, Brown RS, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99. https://doi.org/10.1002/hep.29800.

    Article  PubMed  Google Scholar 

  5. Lu H, Lok AS, Warneke CL, Ahmed S, Torres HA, Martinez F, Suarez-Almazor ME, Foreman JT, Ferrajoli A, Hwang JP. Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review. Lancet Haematol. 2018;5:e474–8. https://doi.org/10.1016/S2352-3026(18)30152-2.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Hsu Y-C, Chen C-Y, Chang I-W, Chang C-Y, Wu C-Y, Lee T-Y, Wu M-S, Bair M-J, Chen J-J, Chen C-C, Tseng C-H, Tai C-M, Huang Y-T, Ku W-H, Mo L-R, Lin J-T. Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial. Lancet Infect Dis. 2021;21:823–33. https://doi.org/10.1016/S1473-3099(20)30692-7.

    Article  CAS  PubMed  Google Scholar 

  7. Holtzman D, Asher AK, Schillie S. The changing epidemiology of hepatitis C virus infection in the United States during the years 2010 to 2018. Am J Public Health. 2021;111:949–55. https://doi.org/10.2105/AJPH.2020.306149.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Chou R, Dana T, Fu R, Zakher B, Wagner J, Ramirez S, Grusing S, Jou JH. Screening for hepatitis C virus infection in adolescents and adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2020;323:976. https://doi.org/10.1001/jama.2019.20788.

    Article  Google Scholar 

  9. Dieterich DT. A simplified algorithm for the management of hepatitis C infection. Gastroenterol Hepatol (N Y). 2019;15:1–12.

    PubMed  Google Scholar 

  10. Ghany MG, Morgan TR, AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71:686–721. https://doi.org/10.1002/hep.31060.

    Article  PubMed  Google Scholar 

  11. Le E, Chee G, Kwan M, Cheung R. Treating the hardest to treat: reframing the hospital admission as an opportunity to initiate hepatitis C treatment. Dig Dis Sci. 2022;67:1244–51. https://doi.org/10.1007/s10620-021-06941-3.

    Article  PubMed  Google Scholar 

  12. Fadnes LT, Aas CF, Vold JH, Leiva RA, Ohldieck C, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg E-M, Johansson KA, INTRO-HCV Study Group. Integrated treatment of hepatitis C virus infection among people who inject drugs: a multicenter randomized controlled trial (INTRO-HCV). PLoS Med. 2021;18:e1003653. https://doi.org/10.1371/journal.pmed.1003653.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpaa ML, McKendrick MW, Nurmikko TJ, Oaklander AL, Oxman MN, Pavan-Langston D, Petersen KL, Rowbotham MC, Schmader KE, Stacey BR, Tyring SK, van Wijck AJM, Wallace MS, Wassilew SW, Whitley RJ. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1–26. https://doi.org/10.1086/510206.

    Article  CAS  PubMed  Google Scholar 

  14. McCrary ML, Severson J, Tyring SK. Varicella zoster virus. J Am Acad Dermatol. 1999;41:1–14; quiz 15–16. https://doi.org/10.1016/s0190-9622(99)70398-1.

    Article  CAS  PubMed  Google Scholar 

  15. Piret J, Boivin G. Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. Curr Opin Infect Dis. 2016;29:654–62. https://doi.org/10.1097/QCO.0000000000000288.

    Article  CAS  PubMed  Google Scholar 

  16. Vrcek I, Choudhury E, Durairaj V. Herpes zoster ophthalmicus: a review for the internist. Am J Med. 2017;130:21–6. https://doi.org/10.1016/j.amjmed.2016.08.039.

    Article  PubMed  Google Scholar 

  17. Shaikh S, Ta CN. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician. 2002;66:1723–30.

    PubMed  Google Scholar 

  18. Lapolla W, Digiorgio C, Haitz K, Magel G, Mendoza N, Grady J, Lu W, Tyring S. Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. Arch Dermatol. 2011;147:901–7. https://doi.org/10.1001/archdermatol.2011.81.

    Article  PubMed  Google Scholar 

  19. Bulilete O, Leiva A, Rullán M, Roca A, Llobera J, PHN Group. Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: a double blind, randomized controlled trial. PLoS One. 2019;14:e0217335. https://doi.org/10.1371/journal.pone.0217335.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Lachiewicz AM, Srinivas ML. Varicella-zoster virus post-exposure management and prophylaxis: a review. Prev Med Rep. 2019;16:101016. https://doi.org/10.1016/j.pmedr.2019.101016.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J. 2008;5:47. https://doi.org/10.1186/1743-422X-5-47.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Galiatsatos P, Shrier I, Lamoureux E, Szilagyi A. Meta-analysis of outcome of cytomegalovirus colitis in immunocompetent hosts. Dig Dis Sci. 2005;50:609–16. https://doi.org/10.1007/s10620-005-2544-6.

    Article  PubMed  Google Scholar 

  23. Tetsuka S, Suzuki T, Ogawa T, Hashimoto R, Kato H. Encephalopathy associated with severe cytomegalovirus infection in an immunocompetent young woman. Case Rep Infect Dis. 2021;2021:5589739. https://doi.org/10.1155/2021/5589739.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Studahl M, Lindquist L, Eriksson B-M, Günther G, Bengner M, Franzen-Röhl E, Fohlman J, Bergström T, Aurelius E. Acute viral infections of the central nervous system in immunocompetent adults: diagnosis and management. Drugs. 2013;73:131–58. https://doi.org/10.1007/s40265-013-0007-5.

    Article  CAS  PubMed  Google Scholar 

  25. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, Gibran NS, Huang M-L, Santo Hayes TK, Corey L, Boeckh M. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300:413–22. https://doi.org/10.1001/jama.300.4.413.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Zhang Z, Liu X, Sang L, Chen S, Wu Z, Zhang J, Sun Y, Huang Y, Xu Y, He W, Li Y, Liu X. Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study. BMC Infect Dis. 2021;21:1026. https://doi.org/10.1186/s12879-021-06698-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Chiche L, Forel J-M, Roch A, Guervilly C, Pauly V, Allardet-Servent J, Gainnier M, Zandotti C, Papazian L. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med. 2009;37:1850–7. https://doi.org/10.1097/CCM.0b013e31819ffea6.

    Article  PubMed  Google Scholar 

  28. Nangle S, Mitra S, Roskos S, Havlichek D. Cytomegalovirus infection in immunocompetent adults: is observation still the best strategy? IDCases. 2018;14:e00442. https://doi.org/10.1016/j.idcr.2018.e00442.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Lancini D, Faddy HM, Flower R, Hogan C. Cytomegalovirus disease in immunocompetent adults. Med J Aust. 2014;201:578–80. https://doi.org/10.5694/mja14.00183.

    Article  PubMed  Google Scholar 

  30. Hakim FA, Tleyjeh IM. Severe adenovirus pneumonia in immunocompetent adults: a case report and review of the literature. Eur J Clin Microbiol Infect Dis. 2008;27:153–8. https://doi.org/10.1007/s10096-007-0416-z.

    Article  CAS  PubMed  Google Scholar 

  31. Humar A, Doucette K, Kumar D, Pang X-L, Lien D, Jackson K, Preiksaitis J. Assessment of adenovirus infection in adult lung transplant recipients using molecular surveillance. J Heart Lung Transplant. 2006;25:1441–6. https://doi.org/10.1016/j.healun.2006.09.015.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Ohori NP, Michaels MG, Jaffe R, Williams P, Yousem SA. Adenovirus pneumonia in lung transplant recipients. Hum Pathol. 1995;26:1073–9. https://doi.org/10.1016/0046-8177(95)90268-6.

    Article  CAS  PubMed  Google Scholar 

  33. Bridevaux P-O, Aubert J-D, Soccal PM, Mazza-Stalder J, Berutto C, Rochat T, Turin L, Van Belle S, Nicod L, Meylan P, Wagner G, Kaiser L. Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax. 2014;69:32–8. https://doi.org/10.1136/thoraxjnl-2013-203581.

    Article  PubMed  Google Scholar 

  34. Chong S, Lee KS, Kim TS, Chung MJ, Chung MP, Han J. Adenovirus pneumonia in adults: radiographic and high-resolution CT findings in five patients. AJR Am J Roentgenol. 2006;186:1288–93. https://doi.org/10.2214/AJR.05.0128.

    Article  PubMed  Google Scholar 

  35. Kim SJ, Kim K, Park SB, Hong DJ, Jhun BW. Outcomes of early administration of cidofovir in non-immunocompromised patients with severe adenovirus pneumonia. PLoS One. 2015;10:e0122642. https://doi.org/10.1371/journal.pone.0122642.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Moon SM, Choe J, Na SJ, Chung CR, Suh GY, Jeon K. Comparative study on the effect of cidofovir treatment for severe adenovirus pneumonia. J Intensive Care Med. 2021;36:1436–42. https://doi.org/10.1177/0885066620960687.

    Article  PubMed  Google Scholar 

  37. Malone B, Urakova N, Snijder EJ, Campbell EA. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Nat Rev Mol Cell Biol. 2022;23:21–39. https://doi.org/10.1038/s41580-021-00432-z.

    Article  CAS  PubMed  Google Scholar 

  38. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, Spijker R, Hooft L, Emperador D, Dittrich S, Domen J, SRA H, Van den Bruel A, Cochrane COVID-19 Diagnostic Test Accuracy Group. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2020;7:CD013665. https://doi.org/10.1002/14651858.CD013665.

    Article  PubMed  Google Scholar 

  39. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020;58:1131–4. https://doi.org/10.1515/cclm-2020-0198.

    Article  CAS  PubMed  Google Scholar 

  40. Mariette X, Hermine O, Tharaux P-L, Resche-Rigon M, Steg PG, Porcher R, Ravaud P. Effectiveness of tocilizumab in patients hospitalized with COVID-19: a follow-up of the CORIMUNO-TOCI-1 randomized clinical trial. JAMA Intern Med. 2021;181:1241–3. https://doi.org/10.1001/jamainternmed.2021.2209.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Potere N, Batticciotto A, Vecchié A, Porreca E, Cappelli A, Abbate A, Dentali F, Bonaventura A. The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol. 2021;17:601–18. https://doi.org/10.1080/1744666X.2021.1919086.

    Article  CAS  PubMed  Google Scholar 

  42. Niu J, Sareli C, Mayer D, Visbal A, Sareli A. Lymphopenia as a predictor for adverse clinical outcomes in hospitalized patients with COVID-19: a single center retrospective study of 4485 cases. J Clin Med. 2022;11:700. https://doi.org/10.3390/jcm11030700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Kovács A, Palásti P, Veréb D, Bozsik B, Palkó A, Kincses ZT. The sensitivity and specificity of chest CT in the diagnosis of COVID-19. Eur Radiol. 2021;31:2819–24. https://doi.org/10.1007/s00330-020-07347-x.

    Article  CAS  PubMed  Google Scholar 

  44. Lawrence Panchali MJ, Oh HJ, Lee YM, Kim C-M, Tariq M, Seo J-W, Kim DY, Yun NR, Kim D-M. Accuracy of real-time polymerase chain reaction in COVID-19 patients. Microbiol Spectr. 2022;10:e0059121. https://doi.org/10.1128/spectrum.00591-21.

    Article  PubMed  Google Scholar 

  45. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, Ladhani S, Zambon M, Gopal R. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill. 2020;25:2001483. https://doi.org/10.2807/1560-7917.ES.2020.25.32.2001483.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Salvatore PP, Dawson P, Wadhwa A, Rabold EM, Buono S, Dietrich EA, Reses HE, Vuong J, Pawloski L, Dasu T, Bhattacharyya S, Pevzner E, Hall AJ, Tate JE, Kirking HL. Epidemiological correlates of polymerase chain reaction cycle threshold values in the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2021;72:e761–7. https://doi.org/10.1093/cid/ciaa1469.

    Article  CAS  PubMed  Google Scholar 

  47. Dadras O, Afsahi AM, Pashaei Z, Mojdeganlou H, Karimi A, Habibi P, Barzegary A, Fakhfouri A, Mirzapour P, Janfaza N, Dehghani S, Afroughi F, Dashti M, Khodaei S, Mehraeen E, Voltarelli F, Sabatier J-M, SeyedAlinaghi S. The relationship between COVID-19 viral load and disease severity: a systematic review. Immun Inflamm Dis. 2022;10:e580. https://doi.org/10.1002/iid3.580.

    Article  CAS  PubMed  Google Scholar 

  48. Trottier CA, Wong B, Kohli R, Boomsma C, Magro F, Kher S, Anderlind C, Golan Y. Dual antiviral therapy for persistent coronavirus disease 2019 and associated organizing pneumonia in an immunocompromised host. Clin Infect Dis. 2023;76:923–5. https://doi.org/10.1093/cid/ciac847.

    Article  PubMed  Google Scholar 

  49. idsa-amp-statement.pdf.

    Google Scholar 

  50. Kevadiya BD, Machhi J, Herskovitz J, Oleynikov MD, Blomberg WR, Bajwa N, Soni D, Das S, Hasan M, Patel M, Senan AM, Gorantla S, McMillan J, Edagwa B, Eisenberg R, Gurumurthy CB, Reid SPM, Punyadeera C, Chang L, Gendelman HE. Diagnostics for SARS-CoV-2 infections. Nat Mater. 2021;20:593–605. https://doi.org/10.1038/s41563-020-00906-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Ferté T, Ramel V, Cazanave C, Lafon M-E, Bébéar C, Malvy D, Georges-Walryck A, Dehail P. Accuracy of COVID-19 rapid antigenic tests compared to RT-PCR in a student population: the StudyCov study. J Clin Virol. 2021;141:104878. https://doi.org/10.1016/j.jcv.2021.104878.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Hertanto DM, Sutanto H, Wiratama BS, Wungu CDK. Modulating the host immune response to fight against COVID-19: where are we in 2021? Virulence. 2021;12:1732–6. https://doi.org/10.1080/21505594.2021.1943275.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704. https://doi.org/10.1056/NEJMoa2021436.

    Article  Google Scholar 

  54. Bhanuprasad K, Manesh A, Devasagayam E, Varghese L, Cherian LM, Kurien R, Karthik R, Deodhar D, Vanjare H, Peter J, Michael JS, Thomas M, Samuel P, Varghese GM. Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic. Int J Infect Dis. 2021;111:267–70. https://doi.org/10.1016/j.ijid.2021.08.037.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Hermine O, Mariette X, Tharaux P-L, Resche-Rigon M, Porcher R, Ravaud P, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual Care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:32–40. https://doi.org/10.1001/jamainternmed.2020.6820.

    Article  CAS  PubMed  Google Scholar 

  56. Hermine O, Mariette X, Porcher R, Djossou F, Nguyen Y, Arlet J-B, Savale L, Diehl JL, Georgin-Lavialle S, Cadranel J, Pialoux G, Lacombe K, Mekinian A, Gros H, Lescure X, Ghosn J, Coupez E, Grapin K, Rapp C, Michel M, Lecapitaine AL, Michot JM, Costedoat-Chalumeau N, Nguyen LBL, Semerano L, Raffi F, Aguillar C, Rouzaud C, Gottenberg JE, Hansmann Y, Bienvenu B, London J, Fantchou FS, Ackermann F, Gros A, Morel A, Gambier N, Sène D, Mégarbane B, Azoulay E, Bureau S, Dougados M, Emmerich J, Fartoukh M, Guidet B, Humbert M, Mahevas M, Pène F, Schlemmer F, Pourcher-Martinez V, Tibi A, Baron G, Perrodeau E, Baron S, Steg G, Yazdapanah Y, Simon T, Resche-Rigon M, Tharaux P-L, Ravaud P. Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: a randomised clinical trial from the CORIMUNO-19 study group. eClinicalMedicine. 2022;46 https://doi.org/10.1016/j.eclinm.2022.101362.

  57. Kramer A, Prinz C, Fichtner F, Fischer A-L, Thieme V, Grundeis F, Spagl M, Seeber C, Piechotta V, Metzendorf M-I, Golinski M, Moerer O, Stephani C, Mikolajewska A, Kluge S, Stegemann M, Laudi S, Skoetz N. Janus kinase inhibitors for the treatment of COVID-19. Cochrane Database Syst Rev. 2022;6:CD015209. https://doi.org/10.1002/14651858.CD015209.

    Article  PubMed  Google Scholar 

  58. Peterson JH, Paranjape NS, Grundlingh N, Priestley JL. Outcomes and adverse effects of baricitinib versus tocilizumab in the management of severe COVID-19. Crit Care Med. 2023;51:337–46. https://doi.org/10.1097/CCM.0000000000005756.

    Article  CAS  PubMed  Google Scholar 

  59. Karampitsakos T, Papaioannou O, Tsiri P, Katsaras M, Katsimpris A, Kalogeropoulos AP, Malakounidou E, Zarkadi E, Tsirikos G, Georgiopoulou V, Sotiropoulou V, Koulousousa E, Chourpiliadi C, Matsioulas A, Lagadinou M, Sampsonas F, Akinosoglou K, Marangos M, Tzouvelekis A. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial. Clin Microbiol Infect. 2023;29:372–8. https://doi.org/10.1016/j.cmi.2022.10.015.

    Article  CAS  PubMed  Google Scholar 

  60. Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, Smith ER, Haber NA, Khanna N, Moher D, Goodman SN, Ioannidis JPA, Hemkens LG. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021;325:1185–95. https://doi.org/10.1001/jama.2021.2747.

    Article  CAS  PubMed  Google Scholar 

  61. Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, Wu D, Agarwal A, Avendaño-Solá C, Bainbridge E, Bar KJ, Devos T, Duarte RF, Gharbharan A, Hsue PY, Kumar G, Luetkemeyer AF, Meyfroidt G, Nicola AM, Mukherjee A, Ortigoza MB, Pirofski L-A, Rijnders BJA, Rokx C, Sancho-Lopez A, Shaw P, Tebas P, Yoon H-A, Grudzen C, Hochman J, Antman EM. Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a meta-analysis. JAMA Netw Open. 2022;5:e2147331. https://doi.org/10.1001/jamanetworkopen.2021.47331.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, Focosi D, Casadevall A, Joyner MJ. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis. JAMA Netw Open. 2023;6:e2250647. https://doi.org/10.1001/jamanetworkopen.2022.50647.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Bloch EM, Focosi D, Shoham S, Senefeld J, Tobian AAR, Baden LR, Tiberghien P, Sullivan D, Cohn C, Dioverti V, Henderson JP, So-Osman C, Juskewitch JE, Razonable RR, Franchini M, Goel R, Grossman BJ, Casadevall A, Joyner MJ, Avery RK, Pirofski L-A, Gebo K. Guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19. Clin Infect Dis. 2023:ciad066. https://doi.org/10.1093/cid/ciad066.

  64. Schwartz IS, Boulware DR, Lee TC. Hydroxychloroquine for COVID19: the curtains close on a comedy of errors. Lancet Reg Health Am. 2022;11:100268. https://doi.org/10.1016/j.lana.2022.100268.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Omrani AS, Pathan SA, Thomas SA, Harris TRE, Coyle PV, Thomas CE, Qureshi I, Bhutta ZA, Mawlawi NA, Kahlout RA, Elmalik A, Azad AM, Daghfal J, Mustafa M, Jeremijenko A, Soub HA, Khattab MA, Maslamani MA, Thomas SH. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine. 2020;29:100645. https://doi.org/10.1016/j.eclinm.2020.100645.

    Article  PubMed  Google Scholar 

  66. Beltran Gonzalez JL, González Gámez M, Mendoza Enciso EA, Esparza Maldonado RJ, Hernández Palacios D, Dueñas Campos S, Robles IO, Macías Guzmán MJ, García Díaz AL, Gutiérrez Peña CM, Martinez Medina L, Monroy Colin VA, Arreola Guerra JM. Efficacy and safety of ivermectin and hydroxychloroquine in patients with severe COVID-19: a randomized controlled trial. Infect Dis Reports. 2022;14:160–8. https://doi.org/10.3390/idr14020020.

    Article  Google Scholar 

  67. Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Proper JL, Siegel LK, Klatt NR, Odde DJ, Luke DG, Anderson B, Karger AB, Ingraham NE, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Lindberg S, Fricton R, Lee S, Zaman A, Saveraid HG, Tordsen WJ, Pullen MF, Biros M, Sherwood NE, Thompson JL, Boulware DR, Murray TA, COVID-OUT Trial Team. Randomized trial of metformin, ivermectin, and fluvoxamine for covid-19. N Engl J Med. 2022;387:599–610. https://doi.org/10.1056/NEJMoa2201662.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Reis G, Silva EASM, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, Campos VHS, Nogueira AMR, de Almeida APFG, Callegari ED, Neto ADF, Savassi LCM, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Guo CM, Rowland-Yeo K, Guyatt GH, Boulware DR, Rayner CR, Mills EJ, TOGETHER Investigators. Effect of early treatment with ivermectin among patients with Covid-19. N Engl J Med. 2022;386:1721–31. https://doi.org/10.1056/NEJMoa2115869.

    Article  CAS  PubMed  Google Scholar 

  69. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh M-D, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group Members. Remdesivir for the treatment of covid-19—final report. N Engl J Med. 2020;383:1813–26. https://doi.org/10.1056/NEJMoa2007764.

    Article  CAS  PubMed  Google Scholar 

  70. Amstutz A, Speich B, Mentré F, Rueegg CS, Belhadi D, Assoumou L, Burdet C, Murthy S, Dodd LE, Wang Y, Tikkinen KAO, Ader F, Hites M, Bouscambert M, Trabaud MA, Fralick M, Lee TC, Pinto R, Barratt-Due A, Lund-Johansen F, Müller F, Nevalainen OPO, Cao B, Bonnett T, Griessbach A, Taji Heravi A, Schönenberger C, Janiaud P, Werlen L, Aghlmandi S, Schandelmaier S, Yazdanpanah Y, Costagliola D, Olsen IC, Briel M. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med. 2023;11:453–64. https://doi.org/10.1016/S2213-2600(22)00528-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA, GS-US-540-9012 (PINETREE) Investigators. Early remdesivir to prevent progression to severe covid-19 in outpatients. N Engl J Med. 2022;386:305–15. https://doi.org/10.1056/NEJMoa2116846.

    Article  CAS  PubMed  Google Scholar 

  72. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022;386:1397–408. https://doi.org/10.1056/NEJMoa2118542.

    Article  CAS  PubMed  Google Scholar 

  73. Liu J, Pan X, Zhang S, Li M, Ma K, Fan C, Lv Y, Guan X, Yang Y, Ye X, Deng X, Wang Y, Qin L, Xia Z, Ge Z, Zhou Q, Zhang X, Ling Y, Qi T, Wen Z, Huang S, Zhang L, Wang T, Liu Y, Huang Y, Li W, Du H, Chen Y, Xu Y, Zhao Q, Zhao R, Annane D, Qu J, Chen D. Efficacy and safety of paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Reg Health West Pac. 2023;33:100694. https://doi.org/10.1016/j.lanwpc.2023.100694.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Anderson AS, Caubel P, Rusnak JM, EPIC-HR Trial Investigators. Nirmatrelvir-ritonavir and viral load rebound in Covid-19. N Engl J Med. 2022;387:1047–9. https://doi.org/10.1056/NEJMc2205944.

    Article  CAS  PubMed  Google Scholar 

  75. Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back DJ, Khoo S. Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlovid) and comedications. Clin Pharmacol Ther. 2022;112:1191–200. https://doi.org/10.1002/cpt.2646.

    Article  CAS  PubMed  Google Scholar 

  76. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A, Assaid C, Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A, Butterton JR, Johnson MG, De Anda C, MOVe-OUT Study Group. Molnupiravir for Oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509–20. https://doi.org/10.1056/NEJMoa2116044.

    Article  PubMed  Google Scholar 

  77. Wang M, Wen W, Zhou M, Wang C, Feng Z. Meta-analysis of risk of myocarditis after messenger RNA COVID-19 vaccine. Am J Cardiol. 2022;167:155–7. https://doi.org/10.1016/j.amjcard.2021.12.007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Prasad S, Kalafat E, Blakeway H, Townsend R, O’Brien P, Morris E, Draycott T, Thangaratinam S, Le Doare K, Ladhani S, von Dadelszen P, Magee LA, Heath P, Khalil A. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. Nat Commun. 2022;13:2414. https://doi.org/10.1038/s41467-022-30052-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Casadevall A, Focosi D. SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern. J Clin Invest. 2023;133:e168603. https://doi.org/10.1172/JCI168603.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133–46. https://doi.org/10.1038/s41579-022-00846-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Global Burden of Disease Long COVID Collaborators, Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, Blyuss O, Bobkova P, Bonsel G, Borzakova S, Buonsenso D, Butnaru D, Carter A, Chu H, De Rose C, Diab MM, Ekbom E, El Tantawi M, Fomin V, Frithiof R, Gamirova A, Glybochko PV, Haagsma JA, Haghjooy Javanmard S, Hamilton EB, Harris G, Heijenbrok-Kal MH, Helbok R, Hellemons ME, Hillus D, Huijts SM, Hultström M, Jassat W, Kurth F, Larsson I-M, Lipcsey M, Liu C, Loflin CD, Malinovschi A, Mao W, Mazankova L, McCulloch D, Menges D, Mohammadifard N, Munblit D, Nekliudov NA, Ogbuoji O, Osmanov IM, Peñalvo JL, Petersen MS, Puhan MA, Rahman M, Rass V, Reinig N, Ribbers GM, Ricchiuto A, Rubertsson S, Samitova E, Sarrafzadegan N, Shikhaleva A, Simpson KE, Sinatti D, Soriano JB, Spiridonova E, Steinbeis F, Svistunov AA, Valentini P, van de Water BJ, van den Berg-Emons R, Wallin E, Witzenrath M, Wu Y, Xu H, Zoller T, Adolph C, Albright J, Amlag JO, Aravkin AY, Bang-Jensen BL, Bisignano C, Castellano R, Castro E, Chakrabarti S, Collins JK, Dai X, Daoud F, Dapper C, Deen A, Duncan BB, Erickson M, Ewald SB, Ferrari AJ, Flaxman AD, Fullman N, Gamkrelidze A, Giles JR, Guo G, Hay SI, He J, Helak M, Hulland EN, Kereselidze M, Krohn KJ, Lazzar-Atwood A, Lindstrom A, Lozano R, Malta DC, Månsson J, Mantilla Herrera AM, Mokdad AH, Monasta L, Nomura S, Pasovic M, Pigott DM, Reiner RC, Reinke G, ALP R, Santomauro DF, Sholokhov A, Spurlock EE, Walcott R, Walker A, Wiysonge CS, Zheng P, Bettger JP, Murray CJL, Vos T. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604–15. https://doi.org/10.1001/jama.2022.18931.

    Article  PubMed Central  Google Scholar 

  82. Stefanou M-I, Palaiodimou L, Bakola E, Smyrnis N, Papadopoulou M, Paraskevas GP, Rizos E, Boutati E, Grigoriadis N, Krogias C, Giannopoulos S, Tsiodras S, Gaga M, Tsivgoulis G. Neurological manifestations of long-COVID syndrome: a narrative review. Ther Adv Chronic Dis. 2022;13:20406223221076890. https://doi.org/10.1177/20406223221076890.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Lai Y-J, Liu S-H, Manachevakul S, Lee T-A, Kuo C-T, Bello D. Biomarkers in long COVID-19: a systematic review. Front Med (Lausanne). 2023;10:1085988. https://doi.org/10.3389/fmed.2023.1085988.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA

    Alexander M. Tatara

Authors
  1. Alexander M. Tatara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander M. Tatara .

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tatara, A.M. (2023). Viral Infection. In: The Infectious Diseases Consult Handbook. Springer, Cham. https://doi.org/10.1007/978-3-031-39474-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-39474-4_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-39473-7

  • Online ISBN: 978-3-031-39474-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation